PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial ResultsGlobeNewsWire • 05/07/25
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 04/23/25
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual MeetingGlobeNewsWire • 04/16/25
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025GlobeNewsWire • 04/08/25
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs UpdateGlobeNewsWire • 03/27/25
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial ResultsGlobeNewsWire • 03/18/25
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal CancerGlobeNewsWire • 03/13/25
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck CancerGlobeNewsWire • 03/07/25
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 02/27/25
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA OncologyGlobeNewsWire • 02/26/25
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer ResearchGlobeNewsWire • 02/24/25
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025GlobeNewsWire • 02/20/25
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a TurnaroundZacks Investment Research • 11/20/24
EMV Capital highlights progress update from portfolio company PDS BiotechProactive Investors • 11/14/24
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern TimeGlobeNewsWire • 11/06/24
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 10/22/24
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and ChemoradiationGlobeNewsWire • 10/02/24